Back to top
more

Ayr Wellness Inc. (AYRWF)

(Delayed Data from OTC)

$0.02 USD

0.02
1,107,357

+0.01 (132.86%)

Updated Aug 7, 2025 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.

Zacks Equity Research

Despite Fast-paced Momentum, Ayr Wellness Inc. (AYRWF) Is Still a Bargain Stock

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -38.46% and 0.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -40% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of -17.86% and 13.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Ayr Wellness Inc. (AYRWF) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Zacks Equity Research

Are Medical Stocks Lagging Haemonetics (HAE) This Year?

by Zacks Equity Research

Here is how Haemonetics (HAE) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -5% and 3.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

National Vision (EYE) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 13.33% and 0.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 10.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 18.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InMode (INMD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

InMode (INMD) delivered earnings and revenue surprises of 2.86% and 0.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Ayr Wellness Inc. (AYRWF), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Fast-paced Momentum Stock Ayr Wellness Inc. (AYRWF) Is Still Trading at a Bargain

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of 71.11% and 5.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Miromatrix Medical Inc. (MIRO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Miromatrix Medical Inc. (MIRO) delivered earnings and revenue surprises of 2.94% and 20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -30.77% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ICU Medical (ICUI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 26.09% and 2.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

QuidelOrtho (QDEL) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 28.57% and 0.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of 48% and 5.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quanterix Corporation (QTRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 5.66% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AdaptHealth Corp. (AHCO) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -96.77% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?